arrow_backAll episodes
EP 44
Modern Drug Delivery Platforms
This episode explores the cutting edge of drug delivery systems, where medicine is moving from traditional formulae to fully programmable systems. The core theme is how artificial intelligence acts as the glue that holds this new paradigm together. The discussion covers the core technical hurdles, including bio-distribution control, intracellular trafficking, manufacturability, and scaling, as well as translation across species.
drug deliveryartificial intelligencelipid nanoparticlesexosomesgene therapy vectorscell therapies
Key Concepts
Artificial Intelligence in Drug Delivery
- AI is used to build predictive surrogate models and employ active learning to select informative experiments.
- AI is used to connect the carrier type to the drug cargo, bridging vast knowledge gaps and transforming from a tool to a scientific partner.
Lipid Nanoparticles
- LNPs are a successful modern delivery platform, with ionizable lipids that can gain a charge and disrupt the endosomal membrane.
- LNPs are being used to target beyond the liver, using ligand display, lipid tuning, and other techniques.
Exosomes
- Exosomes are being explored as a natural delivery technology, with advantages including favorable barrier crossing and biocompatibility.
- Exosomes are difficult to scale and manufacture, requiring rigorous standardization, purification, and batch variability control.
Gene Therapy Vectors
- Gene therapy vectors, such as AAVs, are being engineered to improve tropism specificity and reduce immune responses.
- AI is being used to predict functional variants and streamline the engineering process, and to refine promoters and regulatory elements.
Cell Therapies
- Cell therapies, such as CAR-T and encapsulated cells, are being developed to treat a range of diseases.
- AI is being used to optimize materials and geometry, and to predict the fibrotic response and ensure uniform, reproducible capsules.
Episode Summary
- check_circleThe design space for drug delivery systems is impossibly vast, with countless combinations of polymers, lipids, targeting ligands, and manufacturing processes.
- check_circleArtificial intelligence (AI) is used to build predictive surrogate models that estimate performance without physical testing, and to employ active learning to select informative experiments.
- check_circleThe field has undergone a seismic shift toward structure-function programmability, with hierarchical nanoarchitectures and stimuli-responsive release.
- check_circleBio-distribution control is a major challenge, requiring millimeter precision to get the drug to the right place at the right time.
- check_circleIntracellular trafficking is another hurdle, where the drug must breach the cell's outer defenses and reach a specific compartment inside the cell.
- check_circleManufacturability and scaling are practical challenges, where the complexity of nanoscale structures means scalability and batch variability are massive issues.
- check_circleTranslation across species is a classic hurdle, where what works in a mouse or rat model often fails in human trials due to the complex interplay between the nanoparticle and the human immune system.
- check_circleLipid nanoparticles (LNPs) are a successful modern delivery platform, with ionizable lipids that can gain a charge and disrupt the endosomal membrane to release the nucleic acid cargo.
- check_circleThe growing focus is on targeting beyond the liver, using ligand display, lipid tuning, and other techniques to reach immune cells, the central nervous system, or peripheral tumors.
Full Transcript
Discussion
Join the discussion — sign in to leave a comment.
Log in to comment